Provided by Tiger Fintech (Singapore) Pte. Ltd.

Immunovant, Inc.

15.20
-1.8900-11.06%
Post-market: 15.10-0.1000-0.66%19:58 EDT
Volume:3.71M
Turnover:58.10M
Market Cap:2.58B
PE:-5.81
High:17.09
Open:17.06
Low:15.00
Close:17.09
Loading ...

Is Roivant Sciences Ltd. (NASDAQ:ROIV) One of The Best Stocks to Buy According to Billionaire David Einhorn?

Insider Monkey
·
26 Mar

BUZZ-Street View: Immunovant's muscle drug shows potential as analysts await data on lead candidate

Reuters
·
21 Mar

Buy Rating Affirmed for IMVT-1402: Promising Study Results and Strategic Focus in FcRn Space

TIPRANKS
·
21 Mar

IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite Success

Zacks
·
20 Mar

Immunovant Is Maintained at Buy by B of A Securities

Dow Jones
·
20 Mar

Immunovant price target lowered to $33 from $38 at BofA

TIPRANKS
·
20 Mar

Immunovant Price Target Maintained With a $51.00/Share by HC Wainwright & Co.

Dow Jones
·
20 Mar

Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data

Benzinga
·
20 Mar

Immunovant’s batoclimab shows ‘impressive’ efficacy in MG, says H.C. Wainwright

TIPRANKS
·
20 Mar

Immunovant Shares Down 5.2% After Late-Stage Data for Its Experimental Muscle Disorder Drug

THOMSON REUTERS
·
19 Mar

Roivant says Immunovant announces results from Phase 3 study of batoclimab in MG

TIPRANKS
·
19 Mar

Immunovant's muscle disorder treatment meets main goal in late-stage trial

Reuters
·
19 Mar

Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (Mg) and Chronic Inflammatory Demyelinating Polyneuropathy (Cidp) Studies

THOMSON REUTERS
·
19 Mar

Biohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion Opportunity

Blockhead
·
05 Mar

Analysts Offer Insights on Healthcare Companies: Akero Therapeutics (AKRO), Immunovant (IMVT) and 4D Molecular Therapeutics (FDMT)

TIPRANKS
·
03 Mar

Jefferies Initiates Immunovant at Hold With $20 Price Target

MT Newswires Live
·
03 Mar